Lithium carbonate in the treatment of tardive dyskinesia.
Six patients with tardive dyskinesia were treated with lithium carbonate in an open clinical trial. Evaluations using a new tardive dyskinesia rating scale showed statistically significant improvement in dyskinetic movements while the patients received lithium. This improvement was consistently observed in all patients but was relatively small when compared to the amount of pathology present.
D000368:Aged; D000928:Antidepressive Agents / Q000009:adverse effects; D001714:Bipolar Disorder / Q000188:drug therapy; D002254:Carbonates; D005260:Female; D006801:Humans; D008094:Lithium / Q000627:therapeutic use*; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced* / Q000188:drug therapy; D011619:Psychotropic Drugs / Q000009:adverse effects* / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy; D014149:Tranquilizing Agents / Q000009:adverse effects
D000928:Antidepressive Agents; D002254:Carbonates; D011619:Psychotropic Drugs; D014149:Tranquilizing Agents; D008094:Lithium